Cancer Causes & Control

, Volume 22, Issue 8, pp 1205–1213

Association of secondhand smoke exposures with DNA methylation in bladder carcinomas

  • Charlotte S. Wilhelm-Benartzi
  • Brock C. Christensen
  • Devin C. Koestler
  • E. Andres Houseman
  • Alan R. Schned
  • Margaret R. Karagas
  • Karl T. Kelsey
  • Carmen J. Marsit
Brief report

Abstract

Background

The association between secondhand smoke (SHS) exposure and bladder cancer is inconclusive. Epigenetic alterations in bladder tumors have been linked to primary cigarette smoking and could add to the biological plausibility of an association between SHS exposure and bladder cancer.

Hypothesis

SHS exposure is associated with DNA methylation in bladder tumors.

Methods

Using an array-based approach, we profiled DNA methylation from never smoking cases of incident bladder cancer. Analyses examined associations between individual loci’s methylation with SHS variables (exposure in adulthood, childhood, occupationally, and total exposure). A canonical pathway analysis was used to find pathways significantly associated with each SHS exposure type.

Results

There is a trend toward increased methylation of numerous CpG loci with increasing exposure to adulthood, occupational, and total SHS. Discrete associations between methylation extent of several CpG loci and SHS exposures demonstrated significantly increased methylation of these loci across all types of SHS exposure. CpGs with SHS-related methylation alterations were associated with genes in pathways involved in carcinogenesis, immune modulation, and immune signaling.

Interpretation

Exposures to SHS in adulthood, childhood, occupationally, and in total are each significantly associated with changes in DNA methylation of several CpG loci in bladder tumors, adding biological plausibility to SHS as a risk factor for bladder cancer.

Keywords

Bladder cancer Secondhand smoking DNA methylation Methylation profiling Array-based methodologies 

Supplementary material

10552_2011_9788_MOESM1_ESM.doc (237 kb)
Supplementary material 1 (DOC 237 kb)

References

  1. 1.
    American Cancer Society (2009) Cancer facts and figures 2009. American Cancer Society, Atlanta, GaGoogle Scholar
  2. 2.
    Parkin MP (2008) The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 218:12–20PubMedCrossRefGoogle Scholar
  3. 3.
    Karagas MR, Tosteson TD, Morris JS, Demidenko E, Mott LA, Heaney J et al (2004) Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire. Cancer Causes Control 15(5):465–472PubMedCrossRefGoogle Scholar
  4. 4.
    Boffetta P (2006) Human cancer from environmental pollutants: The epidemiological evidence. Mutat Res 608(2):157–162PubMedGoogle Scholar
  5. 5.
    Wolff EM, Liang G, Jones PA (2005) Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2(10):502–510PubMedCrossRefGoogle Scholar
  6. 6.
    Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374(9685):239–249PubMedCrossRefGoogle Scholar
  7. 7.
    Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L et al (2004) Focus on bladder cancer. Cancer Cell 6(2):111–116PubMedCrossRefGoogle Scholar
  8. 8.
    Silverman DT, Devesa SS, Moore LL (2006) Bladder cancer. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention. Oxford University Press, New York, NY, pp 1101–1127CrossRefGoogle Scholar
  9. 9.
    Jones PA, Ross RK (1999) Prevention of bladder cancer. N Engl J Med 340(18):1424–1426PubMedCrossRefGoogle Scholar
  10. 10.
    Vineis P, Pirastu R (1997) Aromatic amines and cancer. Cancer Causes Control 8(3):346–355PubMedCrossRefGoogle Scholar
  11. 11.
    Skipper PL, Tannenbaum SR, Ross RK, Yu MC (2003) Nonsmoking-related arylamine exposure and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 12(6):503–507PubMedGoogle Scholar
  12. 12.
    Anderson KE, Carmella SG, Ye M, Bliss RL, Le C, Murphy L et al (2001) Metabolites of a tobacco-specific lung carcinogen in nonsmoking women exposed to environmental tobacco smoke. J Natl Cancer Inst 93:378–381PubMedCrossRefGoogle Scholar
  13. 13.
    Vineis P, Alavanja M, Garte S (2004) Dose-response relationship in tobacco-related cancers of bladder and lung: a biochemical interpretation. Int J Cancer 108:2–7PubMedCrossRefGoogle Scholar
  14. 14.
    Talaska G (2003) Aromatic amines and human urinary bladder cancer: exposure sources and epidemiology. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 21(1):29–43PubMedGoogle Scholar
  15. 15.
    Mohtashamipur E, Norpoth K, Lieder F (1987) Urinary excretion of mutagens in smokers of cigarettes with various tar and nicotine yields, black tobacco, and cigars. Cancer Lett 34:103–112PubMedCrossRefGoogle Scholar
  16. 16.
    Riedel K, Scherer G, Engl J, Hagedorn HW, Tricker AR (2006) Determination of three carcinogenic aromatic amines in urine of smokers and nonsmokers. J Anal Toxicol 30(3):187–195PubMedGoogle Scholar
  17. 17.
    Burch JD, Rohan TE, Howe GR, Risch HA, Hill GB, Steele R et al (1989) Risk of bladder cancer by source and type of tobacco exposure: a case-control study. Int J Cancer 44:622–628PubMedCrossRefGoogle Scholar
  18. 18.
    Zeegers MP, Goldbohm RA, van den Brandt PA (2002) A prospective study on active and environmental tobacco smoking and bladder cancer risk (the Netherlands). Cancer Causes Control 13:83–90PubMedCrossRefGoogle Scholar
  19. 19.
    Sandler DP, Everson RB, Wilcox AJ (1985) Passive smoking in adulthood and cancer risk. Am J Epidemiol 121:37–48PubMedGoogle Scholar
  20. 20.
    Jiang X, Yuan JM, Skipper PL (2005) A case-control study of passive smoking and bladder cancer risk among lifelong nonsmokers in Los Angeles. Proc Amer Assoc Cancer Res 46:2210Google Scholar
  21. 21.
    Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6(2):107–116PubMedCrossRefGoogle Scholar
  22. 22.
    Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415–428PubMedGoogle Scholar
  23. 23.
    Marsit CJ, Karagas MR, Danaee H, Liu M, Andrew A, Schned A et al (2006) Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis 27(1):112–116PubMedCrossRefGoogle Scholar
  24. 24.
    Marsit CJ, Houseman EA, Schned AR, Karagas MR, Kelsey KT (2007) Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis 28(8):1745–1751PubMedCrossRefGoogle Scholar
  25. 25.
    Baris D, Karagas MR, Verrill C, Johnson A, Andrew AS, Marsit CJ et al (2009) A case-control study of smoking and bladder cancer risk: emergent patterns over time. J Natl Cancer Inst 101(22):1553–1561PubMedCrossRefGoogle Scholar
  26. 26.
    Karagas MR, Tosteson TD, Blum J, Morris JS, Baron JA, Klaue B (1998) Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a US population. Environ Health Perspect 106(Suppl 4):1047–1050PubMedCrossRefGoogle Scholar
  27. 27.
    Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, Schned AR et al (2005) Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res 65(16):7081–7085PubMedCrossRefGoogle Scholar
  28. 28.
    Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B et al (2006) High-throughput DNA methylation profiling using universal bead arrays. Genome Res 16(3):383–393PubMedCrossRefGoogle Scholar
  29. 29.
    Christensen BC, Kelsey KT, Zheng S, Houseman EA, Marsit CJ, Wrensch MR et al (2010) Breast cancer DNA methylation profiles are associated with tumor size and alcohol and folate intake. PLoS Genet 6(7):e1001043PubMedCrossRefGoogle Scholar
  30. 30.
    Marsit CJ, Houseman EA, Christensen BC, Gagne L, Wrensch MR, Nelson HH et al (2010) Identification of methylated genes associated with aggressive bladder cancer. PLoS One 5(8):e12334PubMedCrossRefGoogle Scholar
  31. 31.
    Hsiung DT, Marsit CJ, Houseman EA, Eddy K, Furniss CS, McClean MD et al (2007) Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 16(1):108–114PubMedCrossRefGoogle Scholar
  32. 32.
    Storey J, Taylor J, Siegmund D (2004) Strong control, conservative point estimation and simulteanous conservative consistency of false discovery rates: a unified approach. J Royal Stat Soc Series B 66(Pt 1):187–205CrossRefGoogle Scholar
  33. 33.
    Ingenuity Pathways Analysis Software (2011) Ingenuity Systems Inc. http://www.ingenuity.com/. Accessed 13 Oct 2010
  34. 34.
    Schlott T, Quentin T, Korabiowska M, Budd B, Kunze E (2004) Alteration of the MDM2–p73-P14ARF pathway related to tumour progression during urinary bladder carcinogenesis. Int J Mol Med 14(5):825–836PubMedGoogle Scholar
  35. 35.
    Schayek H, Bentov I, Sun S, Plymate SR, Werner H (2010) Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. Exp Cell Res 316(9):1479–1488PubMedCrossRefGoogle Scholar
  36. 36.
    Huang Z, Wen Y, Shandilya R, Marks JR, Berchuck A, Murphy SK (2006) High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. Nucleic Acids Res 34(2):555–563PubMedCrossRefGoogle Scholar
  37. 37.
    Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J (2009) Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One 4(12):e8357PubMedCrossRefGoogle Scholar
  38. 38.
    Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ et al (2005) Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res 65(22):10170–10173PubMedCrossRefGoogle Scholar
  39. 39.
    Kuang SQ, Bai H, Fang ZH, Lopez G, Yang H, Tong W et al (2010) Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood 115(12):2412–2419PubMedCrossRefGoogle Scholar
  40. 40.
    Sharma G, Mirza S, Parshad R, Srivastava A, Gupta SD, Pandya P et al (2010) Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci 87(3–4):83–91PubMedCrossRefGoogle Scholar
  41. 41.
    Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003PubMedCrossRefGoogle Scholar
  42. 42.
    Kikuchi R, Tsuda H, Kanai Y, Kasamatsu T, Sengoku K, Hirohashi S et al (2007) Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res 67(15):7095–7105PubMedCrossRefGoogle Scholar
  43. 43.
    Aaronson DS, Horvath CM (2002) A road map for those who don’t know JAK-STAT. Science 296(5573):1653–1655PubMedCrossRefGoogle Scholar
  44. 44.
    Sokol CL, Barton GM, Farr AG, Medzhitov R (2008) A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol 9(3):310–318PubMedCrossRefGoogle Scholar
  45. 45.
    Yang YC, Ciarletta AB, Temple PA, Chung MP, Kovacic S, Witek-Giannotti JS et al (1986) Human IL-3 (multi-CSF): identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell 47(1):3–10PubMedCrossRefGoogle Scholar
  46. 46.
    Maeda A, Maeda T, Liang Y, Yenerel M, Saperstein DA (2006) Effects of cytotoxic T lymphocyte antigen 4 (CTLA4) signaling and locally applied steroid on retinal dysfunction by recoverin, cancer-associated retinopathy antigen. Mol Vis 12:885–891PubMedGoogle Scholar
  47. 47.
    Govers C, Sebestyén Z, Coccoris M, Willemsen RA, Debets R (2010) T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med 16(2):77–87PubMedCrossRefGoogle Scholar
  48. 48.
    Tóvári J, Pirker R, Tímár J, Ostoros G, Kovács G, Döme B (2008) Erythropoietin in cancer: an update. Curr Mol Med 8(6):481–491PubMedCrossRefGoogle Scholar
  49. 49.
    Roberts OL, Holmes K, Müller J, Cross DA, Cross MJ (2009) ERK5 and the regulation of endothelial cell function. Biochem Soc Trans 37(Pt 6):1254–1259PubMedCrossRefGoogle Scholar
  50. 50.
    Zhao Y, Chen X, Cai L, Yang Y, Sui G, Fu S (2010) Angiotensin II/Angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway. J Cell Physiol 225(1):168–173PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Charlotte S. Wilhelm-Benartzi
    • 1
  • Brock C. Christensen
    • 1
    • 2
  • Devin C. Koestler
    • 1
  • E. Andres Houseman
    • 1
  • Alan R. Schned
    • 3
  • Margaret R. Karagas
    • 4
  • Karl T. Kelsey
    • 1
    • 2
  • Carmen J. Marsit
    • 1
    • 2
  1. 1.Department of Community Health Center for Environmental Health and TechnologyBrown UniversityProvidenceUSA
  2. 2.Department of Pathology and Laboratory MedicineBrown UniversityProvidenceUSA
  3. 3.Department of PathologyDartmouth Medical SchoolLebanonUSA
  4. 4.Department of Community and Family MedicineDartmouth Medical SchoolLebanonUSA

Personalised recommendations